A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles.

Autor:	Santana-Mederos D; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Perez-Nicado R; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Climent Y; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Rodriguez L; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Ramirez BS; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Perez-Rodriguez S; National Toxicology Center Havana 11500 Cuba., Rodriguez M; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Labrada C; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Hernandez T; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Diaz M; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Orosa I; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Ramirez U; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Oliva R; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Garrido R; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Cardoso F; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Landys M; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Martinez R; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Gonzalez H; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Hernandez T; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Ochoa-Azze R; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Perez JL; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Enriquez J; National Civil Defense Research Laboratory Mayabeque 32700 Cuba., Gonzalez N; National Civil Defense Research Laboratory Mayabeque 32700 Cuba., Infante Y; National Civil Defense Research Laboratory Mayabeque 32700 Cuba., Espinosa LA; Center for Genetic Engineering and Biotechnology Ave 31 e/158 y 190 Havana 10600 Cuba., Ramos Y; Center for Genetic Engineering and Biotechnology Ave 31 e/158 y 190 Havana 10600 Cuba., González LJ; Center for Genetic Engineering and Biotechnology Ave 31 e/158 y 190 Havana 10600 Cuba., Valenzuela C; Institute of Cybernetics, Mathematics and Physics Havana 10400 Cuba., Casadesus AV; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Fernandez B; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Rojas G; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Pérez-Massón B; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Tundidor Y; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Bermudez E; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Plasencia CA; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Boggiano T; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Ojito E; Center of Molecular Immunology P.O. Box 16040 216 St. Havana Cuba., Chiodo F; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu.; Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Institute of Biomolecular Chemistry, National Research Council (CNR) Pozzuoli Napoli Italy., Fernandez S; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Paquet F; Centre de Biophysique Moléculaire, CNRS UPR 4301, rue Charles Sadron F-45071 Orléans Cedex 2 France., Fang C; Shanghai Fenglin Glycodrug Promotion Center Shanghai 200032 China., Chen GW; Chengdu Olisynn Biotech. Co. Ltd., and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University Chengdu 610041 People's Republic of China., Rivera DG; Laboratory of Synthetic and Biomolecular Chemistry, Faculty of Chemistry, University of Havana, Zapata y G Havana 10400 Cuba dgr@fq.uh.cu., Valdes-Balbin Y; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Garcia-Rivera D; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu., Verez Bencomo V; Finlay Vaccine Institute 200 and 21 Street Havana 11600 Cuba yvbalbin@finlay.edu.cu dagarcia@finlay.edu.cu vicente.verez@finlay.edu.cu.
Jazyk:	angličtina
Zdroj:	RSC chemical biology [RSC Chem Biol] 2021 Dec 08; Vol. 3 (2), pp. 242-249. Date of Electronic Publication: 2021 Dec 08 (Print Publication: 2022).
DOI:	10.1039/d1cb00200g
Abstrakt:	SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its receptor-binding domain (RBD) with the host's cellular receptor. Vaccines seek to block this interaction by eliciting neutralizing antibodies, most of which are directed toward the RBD. Many protein subunit vaccines require powerful adjuvants to generate a potent antibody response. Here, we report on the use of a SARS-CoV-2 dimeric recombinant RBD combined with Neisseria meningitidis outer membrane vesicles (OMVs), adsorbed on alum, as a promising COVID-19 vaccine candidate. This formulation induces a potent and neutralizing immune response in laboratory animals, which is higher than that of the dimeric RBD alone adsorbed on alum. Sera of people vaccinated with this vaccine candidate, named Soberana01, show a high inhibition level of the RBD-ACE2 interaction using RBD mutants corresponding to SARS-CoV-2 variants of concern and wild-type expressed using the phage display technology. To our knowledge, this is the first time that the immunostimulation effect of N. meningitidis OMVs is evaluated in vaccine candidates against SARS-CoV-2. Competing Interests: The authors declare no financial conflicts of interest. Some of the authors are co-inventors on a provisional SARS-CoV-2 vaccine patent (Cu 2020-57) based on these results. (This journal is © The Royal Society of Chemistry.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu